Cowen assumed coverage on shares of Surface Oncology (NASDAQ:SURF) in a research note published on Monday, Marketbeat.com reports. The firm issued an outperform rating on the stock.
Separately, Evercore ISI started coverage on Surface Oncology in a report on Monday. They issued an outperform rating and a $26.00 price objective on the stock.
Shares of Surface Oncology opened at $13.99 on Monday, Marketbeat.com reports. Surface Oncology has a fifty-two week low of $13.75 and a fifty-two week high of $13.75.
About Surface Oncology
Surface Oncology, Inc, a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27.
Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.